Needham Reiterates Buy Rating on MPLT with $42 Price Target
Needham maintained its buy rating on MPLT and set a $42 price target, a 37.84% upside from the current price.
Key Points
- Needham reiterated its buy rating on MPLT with a price target of $42 on June 22, 2026.
- Needham's $42 price target implies 37.84% upside from MapLight Therapeutics, Inc.'s ($MPLT) current $30.47 share price.
- Shares of MPLT traded near $30.47 on Monday, reflecting ongoing interest from institutional investors.
- Major holders like BlackRock and Blue Owl Capital have significantly increased their positions in MPLT.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 22, 2026, Needham reiterated its buy rating on MPLT, setting a price target of $42. This update reflects continued confidence in the company's potential, as MPLT shares traded around $30.47 on Monday.
Needham vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in MPLT
Several institutional investors have shown varying levels of interest in MPLT. Novo Holdings A/S and FCPM III Services B.V. maintained their positions without changes, holding 3,686,622 and 3,226,400 shares, respectively. T. Rowe Price Investment Management added 2,757 shares, bringing its total to 2,801,937 shares valued at approximately $56.96 million, marking a slight 0.1% increase. Goldman Sachs Group increased its holdings by 57,705 shares to 1,994,873, reflecting a 3% growth. BlackRock, Inc. significantly boosted its stake by 244,217 shares, resulting in 1,339,731 shares worth about $27.24 million, a 22.3% increase. Blue Owl Capital Holdings LP made the most notable move, adding 678,871 shares to reach 1,005,929 shares, a 207.6% increase.
Analysts Set New Price Targets
Needham maintained its buy rating on MPLT with a $42 price target on June 22, 2026. Stifel also maintained a buy rating earlier in June, with a target of $36. UBS and Craig-Hallum initiated coverage in late May with buy ratings and targets of $48 and $43, respectively. HC Wainwright & Co. set a $45 target with a buy rating in early May. These ratings highlight a generally positive sentiment among analysts.
Bottom Line
Needham's reiterated buy rating and $42 price target underscore ongoing confidence in MPLT's prospects. The stock's current trading price and recent institutional activity suggest a growing interest in its potential. As always, it's important to remember that analyst ratings are just one piece of the puzzle, and they reflect opinions at a specific point in time.
Get MapLight Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $MPLT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.